Back to today’s briefing

Story perspectives

FDA Approves Lecanemab: New Hope for Alzheimer's Patients

1/28/2025

29 3

Summary

Story summary

Eisai has received FDA approval for lecanemab-irmb, a groundbreaking treatment for early-stage Alzheimer's patients. This new intravenous regimen, administered every four weeks, simplifies the treatment process while targeting harmful amyloid-ß protofibrils to slow cognitive decline. Clinical trials revealed promising cognitive improvements, though some patients faced amyloid-related imaging abnormalities.

1 of 1

Story summary

Eisai has received FDA approval for lecanemab-irmb, a groundbreaking treatment for early-stage Alzheimer's patients. This new intravenous regimen, administered every four weeks, simplifies the treatment process while targeting harmful amyloid-ß protofibrils to slow cognitive decline. Clinical trials revealed promising cognitive improvements, though some patients faced amyloid-related imaging abnormalities.